BLOOD, LYMPH AND RELATED CONDITIONS:@0.084848:0.038601:0.564720:0.038601:0.564720:0.019343:0.084848:0.019343:0.013500:0.010866:0.020438:0.020438:0.017498:0.006515:0.006515:0.008735:0.013923:0.021613:0.013923:0.016063:0.006515:0.017404:0.017404:0.017498:0.006515:0.014276:0.012606:0.010866:0.015466:0.010019:0.012606:0.017498:0.006515:0.019121:0.020438:0.017404:0.017498:0.005315:0.010019:0.005315:0.020438:0.017404:0.011712
80:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
More  recently,  a  number  of  molecular :@0.084848:0.368199:0.481096:0.368199:0.481096:0.352443:0.084848:0.352443:0.017684:0.012604:0.005707:0.012508:0.005330:0.007239:0.005713:0.012508:0.012450:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330:0.005330:0.007241:0.013143:0.005330:0.007243:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330:0.007235:0.012604:0.006042:0.005330:0.007235:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330
markers  have also been  associated with :@0.084848:0.384365:0.481086:0.384365:0.481086:0.368609:0.084848:0.368609:0.018049:0.013143:0.005792:0.009660:0.012508:0.005792:0.007466:0.005330:0.003279:0.011738:0.013143:0.010660:0.012508:0.008621:0.013143:0.003848:0.007466:0.012604:0.008621:0.013123:0.012508:0.012508:0.011738:0.005330:0.003281:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.008621:0.015990:0.003848:0.006523:0.011738:0.005330
prognostication.:@0.084848:0.400531:0.237056:0.400531:0.237056:0.384775:0.084848:0.384775:0.013123:0.005715:0.012604:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
2,5,6:@0.237040:0.394918:0.261900:0.394918:0.261900:0.385732:0.237040:0.385732:0.006215:0.003107:0.006215:0.003107:0.006215
TREATMENT:@0.084848:0.433198:0.197309:0.433198:0.197309:0.415383:0.084848:0.415383:0.008980:0.012401:0.011118:0.015822:0.008980:0.019242:0.011118:0.015822:0.008980
Treatment of AML is  usually  divided  into :@0.084848:0.450514:0.481107:0.450514:0.481107:0.434758:0.084848:0.434758:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.009775:0.012604:0.006042:0.009775:0.014239:0.017684:0.008890:0.009775:0.003848:0.007466:0.005330:0.004457:0.011699:0.007466:0.011699:0.013143:0.003848:0.003848:0.010314:0.005330:0.004458:0.013181:0.003848:0.010660:0.003848:0.013181:0.012508:0.013181:0.005330:0.004460:0.003848:0.011738:0.006523:0.012604:0.005330
induction  of  remission chemotherapy :@0.084848:0.466680:0.481107:0.466680:0.481107:0.450924:0.084848:0.450924:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.014973:0.012604:0.006042:0.005330:0.014971:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.020320:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
and post-remission treatment. Induction :@0.084848:0.482846:0.481098:0.482846:0.481098:0.467090:0.084848:0.467090:0.013143:0.011738:0.013181:0.012277:0.013123:0.012604:0.007466:0.006523:0.006388:0.005711:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.012277:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012277:0.004349:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
chemotherapy  has the goal of reducing :@0.084848:0.499012:0.481094:0.499012:0.481094:0.483256:0.084848:0.483256:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003067:0.011738:0.013143:0.007466:0.008409:0.006523:0.011738:0.012508:0.008409:0.012950:0.012604:0.013143:0.003848:0.008409:0.012604:0.006042:0.008409:0.005713:0.012508:0.013181:0.011699:0.012450:0.003848:0.011738:0.012950:0.005330
the  tumour  bulk to  undetectable levels :@0.084848:0.515178:0.481096:0.515178:0.481096:0.499422:0.084848:0.499422:0.006523:0.011738:0.012508:0.005330:0.005811:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.005809:0.013123:0.011699:0.003848:0.009660:0.011161:0.006523:0.012604:0.005330:0.005811:0.011699:0.011738:0.013181:0.012508:0.006523:0.012508:0.012440:0.006523:0.013143:0.013123:0.003848:0.012508:0.011161:0.003848:0.012508:0.010660:0.012508:0.003848:0.007466:0.005330
(<5% blasts), which is associated with re-:@0.084848:0.531344:0.475756:0.531344:0.475756:0.515588:0.084848:0.515588:0.007100:0.011661:0.010660:0.014913:0.008409:0.013123:0.003848:0.013143:0.007466:0.006523:0.007466:0.007100:0.005330:0.008409:0.015990:0.011738:0.003848:0.012450:0.011738:0.008409:0.003848:0.007466:0.008409:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.008409:0.015990:0.003848:0.006523:0.011738:0.008409:0.005713:0.012508:0.006388
covery of the blood parameters, a condi-:@0.084848:0.547510:0.475777:0.547510:0.475777:0.531754:0.084848:0.531754:0.012450:0.012604:0.010660:0.012508:0.005792:0.010314:0.005850:0.012604:0.006042:0.005850:0.006523:0.011738:0.012508:0.005850:0.013123:0.003848:0.012604:0.012604:0.013181:0.005850:0.013123:0.013143:0.005792:0.013143:0.018049:0.012508:0.006523:0.012508:0.005792:0.007466:0.005330:0.005850:0.013143:0.005850:0.012450:0.012604:0.011738:0.013181:0.003848:0.006388
tion named as complete remission (CR). In :@0.084848:0.563676:0.481101:0.563676:0.481101:0.547920:0.084848:0.547920:0.006523:0.003848:0.012604:0.011738:0.004857:0.011738:0.013143:0.018049:0.012508:0.013181:0.004868:0.013143:0.007466:0.004868:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.004857:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.004868:0.007100:0.015644:0.011680:0.007100:0.005330:0.004868:0.004349:0.011738:0.005330
the first instance, patients will require resus-:@0.084848:0.579842:0.475756:0.579842:0.475756:0.564086:0.084848:0.564086:0.006523:0.011738:0.012508:0.004574:0.004686:0.004686:0.005792:0.007466:0.006523:0.004574:0.003848:0.011738:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.004578:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004584:0.015990:0.003848:0.003848:0.003848:0.004591:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.004580:0.005713:0.012508:0.007466:0.011699:0.007466:0.006388
citation and reversal of all metabolic ab-:@0.084848:0.596008:0.475742:0.596008:0.475742:0.580252:0.084848:0.580252:0.012450:0.003848:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007043:0.013143:0.011738:0.013181:0.007043:0.005713:0.012508:0.010660:0.012508:0.005792:0.007466:0.013143:0.003848:0.007054:0.012604:0.006042:0.007043:0.013143:0.003848:0.003848:0.007056:0.018049:0.012508:0.006523:0.013143:0.013123:0.012604:0.003848:0.003848:0.012450:0.007043:0.013143:0.013123:0.006388
normalities before undertaking  intensive :@0.084848:0.612174:0.481094:0.612174:0.481094:0.596418:0.084848:0.596418:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.011642:0.013123:0.012508:0.006042:0.012604:0.005707:0.012508:0.011642:0.011699:0.011738:0.013181:0.012508:0.005792:0.006523:0.013143:0.009660:0.003848:0.011738:0.012950:0.005330:0.006300:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.005330
combination chemotherapy.  During in-:@0.084848:0.628340:0.475762:0.628340:0.475762:0.612584:0.084848:0.612584:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.014374:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.009029:0.014316:0.011699:0.005792:0.003848:0.011738:0.012950:0.014374:0.003848:0.011738:0.006388
duction therapy, patients will require trans-:@0.084848:0.644506:0.475756:0.644506:0.475756:0.628751:0.084848:0.628751:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.004358:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004358:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004368:0.015990:0.003848:0.003848:0.003848:0.004368:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.004368:0.006523:0.005792:0.013143:0.011738:0.007466:0.006388
fusion with blood products to maintain a :@0.084848:0.660672:0.481088:0.660672:0.481088:0.644917:0.084848:0.644917:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.007832:0.015990:0.003848:0.006523:0.011738:0.007832:0.013123:0.003848:0.012604:0.012604:0.013181:0.007832:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006523:0.007466:0.007832:0.006523:0.012604:0.007832:0.018049:0.013143:0.003848:0.011738:0.006523:0.013143:0.003848:0.011738:0.007832:0.013143:0.005330
haemoglobin level >8 gr/dL and platelet :@0.084848:0.676839:0.481069:0.676839:0.481069:0.661083:0.084848:0.661083:0.011738:0.013143:0.012508:0.018049:0.012604:0.012950:0.003848:0.012604:0.013123:0.003848:0.011738:0.007947:0.003848:0.012508:0.010660:0.012508:0.003848:0.007947:0.011661:0.010660:0.007947:0.012950:0.005792:0.008409:0.013181:0.008890:0.007947:0.013143:0.011738:0.013181:0.007947:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.005330
counts >10 x10 /L.:@0.084848:0.693005:0.250374:0.693049:0.250374:0.677293:0.084848:0.677249:0.012450:0.012604:0.011699:0.011738:0.006523:0.007466:0.005330:0.011661:0.010660:0.010660:0.005330:0.009236:0.010660:0.010660:0.006218:0.008409:0.008890:0.224348
9:@0.221528:0.687430:0.227743:0.687430:0.227743:0.678244:0.221528:0.678244:0.006215
The  treatment  of AML remains unsat-:@0.103035:0.709215:0.475772:0.709215:0.475772:0.693459:0.103035:0.693459:0.008197:0.011738:0.012508:0.005330:0.006302:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.006300:0.012604:0.006042:0.011642:0.014239:0.017684:0.008890:0.011642:0.005713:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.011642:0.011699:0.011738:0.007466:0.013143:0.006523:0.006388
isfactory and the  majority of  patients, :@0.084851:0.725381:0.481108:0.725381:0.481108:0.709625:0.084851:0.709625:0.003848:0.007466:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.014182:0.013143:0.011738:0.013181:0.014182:0.006523:0.011738:0.012508:0.005330:0.008840:0.018049:0.013143:0.003906:0.012604:0.005792:0.003848:0.006523:0.010314:0.014182:0.012604:0.006042:0.005330:0.008842:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330
particularly the older group, are likely to :@0.084851:0.741547:0.481104:0.741547:0.481104:0.725791:0.084851:0.725791:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.008794:0.006523:0.011738:0.012508:0.008794:0.012604:0.003848:0.013181:0.012508:0.005792:0.008794:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.008794:0.013143:0.005715:0.012508:0.008794:0.003848:0.003848:0.009660:0.012508:0.003848:0.010314:0.008794:0.006523:0.012604:0.005330
die of the disease. Myelosuppression is a :@0.084851:0.757713:0.481100:0.757713:0.481100:0.741957:0.084851:0.741957:0.013181:0.003848:0.012508:0.008063:0.012604:0.006042:0.008049:0.006523:0.011738:0.012508:0.008047:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.008063:0.017684:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005715:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.008063:0.003848:0.007466:0.008063:0.013143:0.005330
consequence of the treatment so facilities :@0.084851:0.773879:0.481079:0.773879:0.481079:0.758123:0.084851:0.758123:0.012450:0.012604:0.011738:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.012450:0.012508:0.004768:0.012604:0.006042:0.004780:0.006523:0.011738:0.012508:0.004774:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004772:0.007466:0.012604:0.004780:0.006042:0.013143:0.012450:0.003848:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330
must have capacity for adequate blood-:@0.084851:0.790045:0.475758:0.790045:0.475758:0.774289:0.084851:0.774289:0.018049:0.011699:0.007466:0.006523:0.006427:0.011738:0.013143:0.010660:0.012508:0.006427:0.012450:0.013143:0.013123:0.013143:0.012450:0.003848:0.006523:0.010314:0.006427:0.006042:0.012604:0.005792:0.006415:0.013143:0.013181:0.012508:0.013123:0.011699:0.013143:0.006523:0.012508:0.006417:0.013123:0.003848:0.012604:0.012604:0.013181:0.006388
product  support  (platelets and red  cells) :@0.084851:0.806211:0.481081:0.806211:0.481081:0.790455:0.084851:0.790455:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006523:0.005330:0.003061:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.005330:0.003061:0.007100:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.007466:0.008409:0.013143:0.011738:0.013181:0.008409:0.005713:0.012508:0.013181:0.005330:0.003067:0.012450:0.012508:0.003848:0.003848:0.007466:0.007100:0.005330
and have expertise in the treatment of op-:@0.084851:0.822377:0.475781:0.822377:0.475781:0.806621:0.084851:0.806621:0.013143:0.011738:0.013181:0.004426:0.011738:0.013143:0.010660:0.012508:0.004426:0.012508:0.009236:0.013123:0.012508:0.005792:0.006523:0.003848:0.007466:0.012508:0.004426:0.003848:0.011738:0.004426:0.006523:0.011738:0.012508:0.004426:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004414:0.012604:0.006042:0.004426:0.012604:0.013123:0.006388
portunistic infections.:@0.084851:0.838543:0.279892:0.838543:0.279892:0.822787:0.084851:0.822787:0.013123:0.012604:0.005792:0.006523:0.011699:0.011738:0.003848:0.007466:0.006523:0.003848:0.012450:0.005330:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
Clinical trials over the last 30 years have :@0.103035:0.854709:0.481102:0.854709:0.481102:0.838953:0.103035:0.838953:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005984:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.005984:0.012604:0.010660:0.012508:0.005792:0.005965:0.006523:0.011738:0.012508:0.005967:0.003848:0.013143:0.007466:0.006523:0.005984:0.010660:0.010660:0.005984:0.010314:0.012508:0.013143:0.005792:0.007466:0.005975:0.011738:0.013143:0.010660:0.012508:0.005330
shown that in younger patients (<65 years) :@0.084851:0.870875:0.481075:0.870875:0.481075:0.855119:0.084851:0.855119:0.007466:0.011738:0.012604:0.015990:0.011738:0.004830:0.006523:0.011738:0.013143:0.006523:0.004830:0.003848:0.011738:0.004830:0.010314:0.012604:0.011699:0.011738:0.012950:0.012508:0.005792:0.004814:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004830:0.007100:0.011661:0.010660:0.010660:0.004830:0.010314:0.012508:0.013143:0.005792:0.007466:0.007100:0.005330
one or two cycles of a combination con-:@0.084851:0.887041:0.475772:0.887041:0.475772:0.871285:0.084851:0.871285:0.012604:0.011738:0.012508:0.006696:0.012604:0.005792:0.006696:0.006523:0.015990:0.012604:0.006696:0.012450:0.010314:0.012450:0.003848:0.012508:0.007466:0.006708:0.012604:0.006042:0.006696:0.013143:0.006696:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006696:0.012450:0.012604:0.011738:0.006388
taining cytarabine at 100-200  mg/m  for :@0.084851:0.903207:0.481091:0.903245:0.481091:0.887489:0.084851:0.887451:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.009275:0.012450:0.010314:0.006523:0.013143:0.005792:0.013143:0.013123:0.003848:0.011738:0.012508:0.009275:0.013143:0.006523:0.009275:0.010660:0.010660:0.010660:0.006388:0.010660:0.010660:0.010660:0.005330:0.003974:0.018049:0.012950:0.008409:0.018049:0.006226:0.009275:0.006042:0.012604:0.005792:-0.312110
2:@0.435831:0.897626:0.442046:0.897626:0.442046:0.888441:0.435831:0.888441:0.006215
seven  days and  an  anthracycline  antibi-:@0.084852:0.919411:0.475755:0.919411:0.475755:0.903656:0.084852:0.903656:0.007466:0.012508:0.010660:0.012508:0.011738:0.005330:0.002896:0.013181:0.013143:0.010314:0.007466:0.008236:0.013143:0.011738:0.013181:0.005330:0.002896:0.013143:0.011738:0.005330:0.002894:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005330:0.002892:0.013143:0.011738:0.006523:0.003848:0.013123:0.003848:0.006388
otic such as daunorubicin (75-90 mg/m ) :@0.084852:0.935577:0.481085:0.935583:0.481085:0.919827:0.084852:0.919822:0.012604:0.006523:0.003848:0.012450:0.007947:0.007466:0.011699:0.012450:0.011738:0.007947:0.013143:0.007466:0.007947:0.013181:0.013143:0.011699:0.011738:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.007947:0.007100:0.010660:0.010660:0.006388:0.010660:0.010660:0.007961:0.018049:0.012950:0.008409:0.018049:0.006214:0.007100:-0.359140
2:@0.462437:0.929964:0.468652:0.929964:0.468652:0.920779:0.462437:0.920779:0.006215
or idarubicin (12 mg/m ) for three days (7+3 :@0.524245:0.096166:0.920480:0.096166:0.920480:0.080410:0.524245:0.080410:0.012600:0.005786:0.004378:0.003656:0.012989:0.012950:0.005600:0.011507:0.012931:0.003656:0.012257:0.003656:0.011545:0.004183:0.006908:0.010468:0.010468:0.004183:0.017857:0.012758:0.008217:0.018049:0.005928:0.006908:0.004185:0.005850:0.012411:0.005600:0.004185:0.006331:0.011545:0.005521:0.012315:0.012315:0.004183:0.012989:0.012950:0.010122:0.007274:0.004183:0.006908:0.010468:0.011468:0.010664:0.422435
2:@0.730670:0.090547:0.736885:0.090547:0.736885:0.081361:0.730670:0.081361:0.006215
regimen) leads to CR in 50-80% (depend-:@0.524242:0.112636:0.915111:0.112636:0.915111:0.096880:0.524242:0.096880:0.005521:0.012315:0.012758:0.003656:0.017857:0.012315:0.011545:0.006908:0.007793:0.003656:0.012315:0.012950:0.012989:0.007274:0.007793:0.006331:0.012411:0.007793:0.015452:0.011488:0.007793:0.003656:0.011545:0.007793:0.010468:0.010468:0.006196:0.010468:0.010468:0.014720:0.007793:0.006908:0.012989:0.012315:0.012931:0.012315:0.011545:0.012989:0.006388
ing on risk factors), particularly in patients :@0.524242:0.129106:0.920522:0.129106:0.920522:0.113350:0.524242:0.113350:0.003656:0.011545:0.012758:0.008063:0.012411:0.011545:0.008063:0.005600:0.003656:0.007274:0.009467:0.008063:0.005850:0.012950:0.012257:0.006331:0.012411:0.005600:0.007274:0.006908:0.005138:0.008063:0.012931:0.012950:0.005600:0.006331:0.003656:0.012257:0.011507:0.003656:0.012950:0.005600:0.003656:0.010122:0.008063:0.003656:0.011545:0.008063:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007468:0.005330
with favourable and intermediate-risk cy-:@0.524242:0.145577:0.915144:0.145577:0.915144:0.129821:0.524242:0.129821:0.015798:0.003656:0.006331:0.011545:0.009025:0.005850:0.012950:0.010468:0.012411:0.011507:0.005600:0.012950:0.012931:0.003656:0.012315:0.009025:0.012950:0.011545:0.012989:0.009025:0.003656:0.011545:0.006331:0.012315:0.006131:0.017857:0.012315:0.012989:0.003656:0.012950:0.006331:0.012315:0.006196:0.005600:0.003656:0.007274:0.009467:0.009025:0.012257:0.010122:0.006388
togenetics.  AML in remission is defined as :@0.524242:0.162047:0.920478:0.162054:0.920478:0.146298:0.524242:0.146291:0.006331:0.012411:0.012758:0.012315:0.011545:0.012315:0.006331:0.003656:0.012257:0.007274:0.005330:0.005898:0.007143:0.014047:0.017491:0.008698:0.007143:0.003656:0.011545:0.007143:0.005521:0.012315:0.017857:0.003656:0.007274:0.007274:0.003656:0.012411:0.011545:0.007143:0.003656:0.007274:0.007143:0.012989:0.012315:0.004589:0.004589:0.011545:0.012315:0.012989:0.007143:0.012950:0.007470:0.326599
7:@0.626559:0.156435:0.632773:0.156435:0.632773:0.147250:0.626559:0.147250:0.006215
a normal peripheral blood-cell count (ab-:@0.524233:0.178525:0.915136:0.178525:0.915136:0.162769:0.524233:0.162769:0.012950:0.006839:0.011545:0.012411:0.006131:0.017857:0.012950:0.003656:0.006839:0.012931:0.012315:0.005600:0.003656:0.012931:0.011545:0.012315:0.005600:0.012950:0.003656:0.006841:0.012931:0.003656:0.012411:0.012411:0.012989:0.006196:0.012257:0.012315:0.003656:0.003656:0.006839:0.012257:0.012411:0.011507:0.011545:0.006331:0.006839:0.006908:0.012950:0.012931:0.006388
solute neutrophil  count >1,000/mm   and :@0.524233:0.194995:0.920489:0.194998:0.920489:0.179242:0.524233:0.179239:0.007274:0.012411:0.003656:0.011507:0.006331:0.012315:0.011449:0.011545:0.012315:0.011507:0.006331:0.005519:0.012411:0.012931:0.011545:0.003656:0.003656:0.005330:0.006109:0.012257:0.012411:0.011507:0.011545:0.006331:0.011449:0.011468:0.010468:0.005138:0.010468:0.010468:0.010468:0.008217:0.017857:0.018049:0.005899:0.005330:0.006119:0.012950:0.011545:0.013181:0.278670
3:@0.859928:0.189379:0.866143:0.189379:0.866143:0.180194:0.859928:0.180194:0.006215
platelet count >100,000/mm ) and nor-:@0.524249:0.211469:0.915153:0.211470:0.915153:0.195714:0.524249:0.195713:0.012931:0.003656:0.012950:0.006331:0.012315:0.003656:0.012315:0.006331:0.014143:0.012257:0.012411:0.011507:0.011545:0.006331:0.014143:0.011468:0.010468:0.010468:0.010468:0.005138:0.010468:0.010468:0.010468:0.008217:0.017857:0.018049:0.005921:0.006908:0.014143:0.012950:0.011545:0.012989:0.014143:0.011545:0.012411:0.005600:0.261104
3:@0.800425:0.205851:0.806639:0.205851:0.806639:0.196666:0.800425:0.196666:0.006215
mocellular bone marrow with less than :@0.524244:0.227941:0.920516:0.227941:0.920516:0.212185:0.524244:0.212185:0.017857:0.012411:0.012257:0.012315:0.003656:0.003656:0.011507:0.003656:0.012950:0.005600:0.013066:0.012931:0.012411:0.011545:0.012315:0.013066:0.017857:0.012950:0.005600:0.005521:0.012411:0.015798:0.013066:0.015798:0.003656:0.006331:0.011545:0.013066:0.003656:0.012315:0.007274:0.007274:0.013066:0.006331:0.011545:0.012950:0.011734:0.005330
5% blasts and no signs or symptoms of the :@0.524244:0.244411:0.920481:0.244411:0.920481:0.228655:0.524244:0.228655:0.010468:0.014720:0.006581:0.012931:0.003656:0.012950:0.007274:0.006331:0.007274:0.006581:0.012950:0.011545:0.012989:0.006581:0.011545:0.012411:0.006581:0.007274:0.003656:0.012758:0.011545:0.007274:0.006581:0.012411:0.005600:0.006581:0.007274:0.010122:0.017857:0.012931:0.006331:0.012411:0.017857:0.007274:0.006581:0.012411:0.005850:0.006581:0.006331:0.011545:0.012506:0.005330
disease. Achieving remission may be ad-:@0.524244:0.260881:0.915151:0.260881:0.915151:0.245125:0.524244:0.245125:0.012989:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.005138:0.008948:0.014047:0.012257:0.011545:0.003656:0.012315:0.010468:0.003656:0.011545:0.012758:0.008948:0.005521:0.012315:0.017857:0.003656:0.007274:0.007274:0.003656:0.012411:0.011545:0.008948:0.017857:0.012950:0.010122:0.008948:0.012931:0.012315:0.008948:0.012950:0.012989:0.006388
versely affected by clinical factors such as :@0.524244:0.277352:0.920504:0.277352:0.920504:0.261596:0.524244:0.261596:0.010468:0.012315:0.005600:0.007274:0.012315:0.003656:0.010122:0.005984:0.012950:0.005905:0.005850:0.012315:0.012257:0.006331:0.012315:0.012989:0.005984:0.012931:0.010122:0.005984:0.012257:0.003656:0.003656:0.011545:0.003656:0.012257:0.012950:0.003656:0.005984:0.005850:0.012950:0.012257:0.006331:0.012411:0.005600:0.007274:0.005984:0.007274:0.011507:0.012257:0.011545:0.005984:0.012950:0.007470:0.005330
advanced age, poor performance status, :@0.524244:0.293822:0.920483:0.293822:0.920483:0.278066:0.524244:0.278066:0.012950:0.012989:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.006465:0.012950:0.012758:0.012315:0.005138:0.006465:0.012931:0.012411:0.012411:0.005600:0.006465:0.012931:0.012315:0.006515:0.005850:0.012411:0.006129:0.017857:0.012950:0.011545:0.012257:0.012315:0.006465:0.007274:0.006331:0.012950:0.006331:0.011507:0.007274:0.005328:0.005330
leukocyte >30x10 /L, antecedent haema-:@0.524244:0.310292:0.915178:0.310303:0.915178:0.294547:0.524244:0.294536:0.003656:0.012315:0.011507:0.009467:0.012411:0.012257:0.010122:0.006331:0.012315:0.008370:0.011468:0.010468:0.010468:0.009044:0.010468:0.010660:0.005913:0.008217:0.008698:0.005138:0.008370:0.012950:0.011545:0.006331:0.012315:0.012257:0.012315:0.012989:0.012315:0.011545:0.006331:0.008370:0.011545:0.012950:0.012315:0.017857:0.012950:0.117323
9:@0.685380:0.304684:0.691595:0.304684:0.691595:0.295499:0.685380:0.295499:0.006215
tological disorder (myelodysplasia or my-:@0.524249:0.326773:0.915138:0.326773:0.915138:0.311018:0.524249:0.311018:0.006331:0.012411:0.003656:0.012411:0.012758:0.003656:0.012257:0.012950:0.003656:0.009660:0.012989:0.003656:0.007274:0.012411:0.005482:0.012989:0.012315:0.005600:0.009660:0.006908:0.017857:0.010122:0.012315:0.003656:0.012411:0.012989:0.010122:0.007274:0.012931:0.003656:0.012950:0.007274:0.003656:0.012950:0.009660:0.012411:0.005600:0.009660:0.017857:0.010122:0.006388
eloproliferative syndrome) and therapy of :@0.524249:0.343244:0.920491:0.343244:0.920491:0.327488:0.524249:0.327488:0.012315:0.003656:0.012411:0.012931:0.005519:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006331:0.003656:0.010468:0.012315:0.007549:0.007274:0.010122:0.011545:0.012989:0.005519:0.012411:0.017857:0.012315:0.006908:0.007551:0.012950:0.011545:0.012989:0.007551:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.007551:0.012411:0.006042:0.005330
another malignancy.  Alternatively, epige-:@0.524249:0.359714:0.915159:0.359720:0.915159:0.343964:0.524249:0.343958:0.012950:0.011545:0.012411:0.006331:0.011545:0.012315:0.005600:0.006263:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.012257:0.010122:0.005330:0.005892:0.006263:0.014047:0.003656:0.006331:0.012315:0.006000:0.011545:0.012950:0.006331:0.003656:0.010468:0.012315:0.003656:0.010122:0.005138:0.006273:0.012315:0.012931:0.003656:0.012758:0.012315:0.045463
8:@0.717625:0.354101:0.723840:0.354101:0.723840:0.344915:0.717625:0.344915:0.006215
netic modifications of malignant cells with :@0.524244:0.376190:0.920481:0.376190:0.920481:0.360434:0.524244:0.360434:0.011545:0.012315:0.006331:0.003656:0.012257:0.006820:0.017857:0.012411:0.012989:0.003656:0.004589:0.004589:0.012257:0.012950:0.006331:0.003656:0.012411:0.011545:0.007274:0.006821:0.012411:0.005850:0.006820:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.006331:0.006820:0.012257:0.012315:0.003656:0.003656:0.007274:0.006820:0.015798:0.003656:0.006331:0.011734:0.005330
5-azacytidine (Vidaza) or decytabine (Da-:@0.524244:0.392660:0.915153:0.392660:0.915153:0.376904:0.524244:0.376904:0.010468:0.006196:0.012950:0.007986:0.012950:0.012257:0.010122:0.006331:0.003656:0.012989:0.003656:0.011545:0.012315:0.005984:0.006908:0.013412:0.003656:0.012989:0.012950:0.007986:0.012950:0.006908:0.005984:0.012411:0.005600:0.005984:0.012989:0.012315:0.012257:0.010122:0.006331:0.012950:0.012931:0.003656:0.011545:0.012315:0.005984:0.006908:0.014124:0.012950:0.006388
cogen) have also been associated with :@0.524244:0.409130:0.920520:0.409130:0.920520:0.393375:0.524244:0.393375:0.012257:0.012411:0.012758:0.012315:0.011545:0.006908:0.010429:0.011545:0.012950:0.010468:0.012315:0.010429:0.012950:0.003656:0.007274:0.012411:0.010429:0.012931:0.012315:0.012315:0.011545:0.010429:0.012950:0.007274:0.007274:0.012411:0.012257:0.003656:0.012950:0.006331:0.012315:0.012989:0.010429:0.015798:0.003656:0.006331:0.011736:0.005330
marrow recovery, particularly if there is an :@0.524244:0.425601:0.920508:0.425601:0.920508:0.409845:0.524244:0.409845:0.017857:0.012950:0.005600:0.005519:0.012411:0.015798:0.006716:0.005521:0.012315:0.012257:0.012411:0.010468:0.012315:0.005600:0.010122:0.005138:0.006716:0.012931:0.012950:0.005600:0.006331:0.003656:0.012257:0.011507:0.003656:0.012950:0.005600:0.003656:0.010122:0.006716:0.003656:0.005850:0.006716:0.006331:0.011545:0.012315:0.005519:0.012315:0.006716:0.003656:0.007274:0.006716:0.012950:0.011734:0.005330
antecedent marrow disorder, and are cur-:@0.524244:0.442071:0.915172:0.442071:0.915172:0.426315:0.524244:0.426315:0.012950:0.011545:0.006331:0.012315:0.012257:0.012315:0.012989:0.012315:0.011545:0.006331:0.006009:0.017857:0.012950:0.005600:0.005521:0.012411:0.015798:0.006011:0.012989:0.003656:0.007274:0.012411:0.005482:0.012989:0.012315:0.003575:0.005138:0.006009:0.012950:0.011545:0.012989:0.006009:0.012950:0.005519:0.012315:0.006009:0.012257:0.011507:0.005600:0.006388
rently being actively studied in this group.:@0.524244:0.458541:0.900004:0.458541:0.900004:0.442785:0.524244:0.442785:0.005521:0.012315:0.011545:0.006331:0.003656:0.010122:0.004965:0.012931:0.012315:0.003656:0.011545:0.012758:0.004965:0.012950:0.012257:0.006331:0.003656:0.010468:0.012315:0.003656:0.010122:0.004965:0.007274:0.006331:0.011507:0.012989:0.003656:0.012315:0.012989:0.004965:0.003656:0.011545:0.004965:0.006331:0.011545:0.003656:0.007274:0.004965:0.012758:0.005519:0.012411:0.011507:0.012931:0.005330
2,8:@0.899835:0.452933:0.915148:0.452933:0.915148:0.443748:0.899835:0.443748:0.006103:0.002995:0.006215
Patients  with promyelocytic leukaemia :@0.542424:0.475024:0.920489:0.475024:0.920489:0.459268:0.542424:0.459268:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004243:0.015990:0.003848:0.006523:0.011738:0.009583:0.013123:0.005715:0.012604:0.018049:0.010314:0.012508:0.003848:0.012604:0.012450:0.010314:0.006523:0.003848:0.012450:0.009583:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330
require a different approach both in sup-:@0.524240:0.491495:0.915161:0.491495:0.915161:0.475739:0.524240:0.475739:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.006870:0.013143:0.006870:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.006860:0.013143:0.013123:0.013123:0.005721:0.012604:0.013143:0.012450:0.011738:0.006870:0.013123:0.012604:0.006523:0.011738:0.006870:0.003848:0.011738:0.006870:0.007466:0.011699:0.013123:0.006388
portive therapy as well as for the treatment :@0.524240:0.507965:0.920506:0.507965:0.920506:0.492209:0.524240:0.492209:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.003837:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.003848:0.013143:0.007466:0.003848:0.015990:0.012508:0.003848:0.003848:0.003848:0.013143:0.007466:0.003848:0.006042:0.012604:0.005792:0.003831:0.006523:0.011738:0.012508:0.003833:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of the malignancy. Due to severe coagu-:@0.524240:0.524435:0.915168:0.524435:0.915168:0.508679:0.524240:0.508679:0.012604:0.006042:0.006119:0.006523:0.011738:0.012508:0.006119:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.005330:0.006119:0.014316:0.011699:0.012508:0.006119:0.006523:0.012604:0.006119:0.007466:0.012508:0.010660:0.012508:0.005715:0.012508:0.006119:0.012450:0.012604:0.013143:0.012950:0.011699:0.006388
lopathy,  such  patients need  aggressive :@0.524240:0.540906:0.920481:0.540906:0.920481:0.525150:0.524240:0.525150:0.003848:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.005330:0.005330:0.006396:0.007466:0.011699:0.012450:0.011738:0.005330:0.006398:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011738:0.011738:0.012508:0.012508:0.013181:0.005330:0.006398:0.013143:0.012950:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330
replacement  of  coagulation  factors  with :@0.524240:0.557376:0.920483:0.557376:0.920483:0.541620:0.524240:0.541620:0.005713:0.012508:0.013123:0.003848:0.013143:0.012450:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330:0.003042:0.012604:0.006042:0.005330:0.003046:0.012450:0.012604:0.013143:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.003038:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.003040:0.015990:0.003848:0.006523:0.011738:0.005330
blood products to prevent bleeding. Since :@0.524240:0.573846:0.920495:0.573846:0.920495:0.558090:0.524240:0.558090:0.013123:0.003848:0.012604:0.012604:0.013181:0.004349:0.013123:0.005711:0.012604:0.013181:0.011699:0.012450:0.006523:0.007466:0.004349:0.006523:0.012604:0.004349:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.004349:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330:0.004349:0.009583:0.003848:0.011738:0.012450:0.012508:0.005330
all trans retinoic acid (ATRA; Vesenoid) can :@0.524240:0.590317:0.920473:0.590317:0.920473:0.574561:0.524240:0.574561:0.013143:0.003848:0.003848:0.004091:0.006523:0.005792:0.013143:0.011738:0.007466:0.004079:0.005711:0.012508:0.006523:0.003848:0.011738:0.012604:0.003848:0.012450:0.004079:0.013143:0.012450:0.003848:0.013181:0.004079:0.007100:0.012677:0.008197:0.011680:0.014239:0.005330:0.004068:0.011567:0.012508:0.007466:0.012508:0.011738:0.012604:0.003848:0.013181:0.007100:0.004079:0.012450:0.013143:0.011738:0.005330
reverse the block in differentiation typical :@0.524240:0.606787:0.920475:0.606787:0.920475:0.591031:0.524240:0.591031:0.005713:0.012508:0.010660:0.012508:0.005792:0.007466:0.012508:0.006523:0.006523:0.011738:0.012508:0.006514:0.013123:0.003848:0.012604:0.012450:0.009660:0.006523:0.003848:0.011738:0.006523:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.006514:0.006523:0.010314:0.013123:0.003848:0.012450:0.013143:0.003848:0.005330
of the disease caused by the chimeric :@0.524240:0.623257:0.920491:0.623257:0.920491:0.607501:0.524240:0.607501:0.012604:0.006042:0.011007:0.006523:0.011738:0.012508:0.011007:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012519:0.011007:0.012450:0.013143:0.011699:0.007466:0.012508:0.013181:0.011007:0.013123:0.010314:0.011007:0.006523:0.011738:0.012508:0.011007:0.012450:0.011738:0.003848:0.018049:0.012508:0.005792:0.003848:0.012450:0.005330
PML-RARa  protein product,  combination :@0.524240:0.639727:0.920491:0.639727:0.920491:0.623972:0.524240:0.623972:0.011392:0.017684:0.008890:0.006388:0.011680:0.014239:0.011680:0.013143:0.005330:0.004489:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.009833:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006523:0.005330:0.005330:0.004489:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
of  daily ATRA  (40 mg/m ) with anthracy-:@0.524240:0.656198:0.915166:0.656218:0.915166:0.640462:0.524240:0.640442:0.012604:0.006042:0.005330:0.003433:0.013181:0.013143:0.003848:0.003848:0.010314:0.008775:0.012675:0.008197:0.011680:0.014239:0.005330:0.003427:0.007100:0.010660:0.010660:0.008775:0.018049:0.012950:0.008409:0.018049:0.006229:0.007100:0.008775:0.015990:0.003848:0.006523:0.011738:0.008775:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:-0.385813
2:@0.754971:0.650599:0.761186:0.650599:0.761186:0.641413:0.754971:0.641413:0.006215
cline chemotherapy has been associated :@0.524238:0.672688:0.920464:0.672688:0.920464:0.656932:0.524238:0.656932:0.012450:0.003848:0.003848:0.011738:0.012508:0.005369:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012494:0.005792:0.013143:0.013123:0.010314:0.005369:0.011738:0.013143:0.007466:0.005369:0.013123:0.012508:0.012508:0.011738:0.005369:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
with a nearly 90% remission rate. Prescrip-:@0.524238:0.689158:0.915139:0.689158:0.915139:0.673402:0.524238:0.673402:0.015990:0.003848:0.006523:0.011738:0.006812:0.013143:0.006812:0.011738:0.012508:0.013143:0.005792:0.003848:0.010314:0.006812:0.010660:0.010660:0.014913:0.006812:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.006812:0.005792:0.013143:0.006523:0.012508:0.005330:0.006812:0.011392:0.005709:0.012508:0.007466:0.012450:0.005792:0.003848:0.013123:0.006388
tion of ATRA can lead to hyperleukocyto-:@0.524238:0.705629:0.915147:0.705629:0.915147:0.689873:0.524238:0.689873:0.006523:0.003848:0.012604:0.011738:0.006600:0.012604:0.006042:0.006600:0.012675:0.008197:0.011680:0.014239:0.006587:0.012450:0.013143:0.011738:0.006600:0.003848:0.012508:0.013143:0.013181:0.006600:0.006523:0.012604:0.006600:0.011738:0.010314:0.013123:0.012508:0.005792:0.003848:0.012508:0.011699:0.009660:0.012604:0.012450:0.010314:0.006523:0.012565:0.006388
sis and respiratory distress, now known as :@0.524238:0.722099:0.920458:0.722099:0.920458:0.706343:0.524238:0.706343:0.007466:0.003848:0.007466:0.007522:0.013143:0.011738:0.013181:0.007505:0.005713:0.012508:0.007466:0.013123:0.003848:0.005792:0.013143:0.006523:0.012604:0.005792:0.010314:0.007505:0.013181:0.003848:0.007466:0.006523:0.005719:0.012508:0.007466:0.007466:0.005330:0.007505:0.011738:0.012604:0.015990:0.007505:0.009660:0.011738:0.012604:0.015990:0.011738:0.007505:0.013143:0.007466:0.005330
the  differentiation  syndrome,  which  can :@0.524238:0.738569:0.920491:0.738569:0.920491:0.722813:0.524238:0.722813:0.006523:0.011738:0.012508:0.005330:0.004737:0.013181:0.003848:0.006104:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.004741:0.007466:0.010314:0.011738:0.013181:0.005717:0.012604:0.018049:0.012508:0.005330:0.005330:0.004743:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330:0.004743:0.012450:0.013143:0.011738:0.005330
be prevented  by early administration of :@0.524238:0.755040:0.920502:0.755040:0.920502:0.739284:0.524238:0.739284:0.013123:0.012508:0.009544:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.012508:0.013181:0.005330:0.004201:0.013123:0.010314:0.009544:0.012508:0.013143:0.005792:0.003848:0.010314:0.009544:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.009544:0.012604:0.006042:0.005330
corticosteroids.  Molecular remission  (un-:@0.524238:0.771510:0.915141:0.771510:0.915141:0.755754:0.524238:0.755754:0.012450:0.012604:0.005792:0.006523:0.003848:0.012450:0.012604:0.007466:0.006523:0.012508:0.005700:0.012604:0.003848:0.013181:0.007466:0.005330:0.005330:0.006754:0.017684:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.012084:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.006766:0.007100:0.011699:0.011738:0.006388
detectable  PML-RARa  on  PCR)  following :@0.524238:0.787980:0.920487:0.787980:0.920487:0.772224:0.524238:0.772224:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.003641:0.011392:0.017684:0.008890:0.006388:0.011680:0.014239:0.011680:0.013143:0.005330:0.003635:0.012604:0.011738:0.005330:0.003637:0.011392:0.015644:0.011680:0.007100:0.005330:0.003645:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
intensification  therapy  is  associated  with :@0.524238:0.804450:0.920473:0.804450:0.920473:0.788695:0.524238:0.788695:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.003848:0.004686:0.004686:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.004331:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004333:0.003848:0.007466:0.005330:0.004347:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.004341:0.015990:0.003848:0.006523:0.011738:0.005330
favourable long-term outcome.  The in-:@0.524238:0.820921:0.915148:0.820939:0.915148:0.805183:0.524238:0.805165:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.011257:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006315:0.018049:0.011257:0.012604:0.011699:0.006523:0.012450:0.012604:0.018036:0.012508:0.005330:0.006226:0.011257:0.008197:0.011738:0.012508:0.011257:0.003848:0.011738:-0.625390
9:@0.832000:0.815320:0.838215:0.815320:0.838215:0.806134:0.832000:0.806134:0.006215
clusion of arsenic trioxide (ATO) as part of :@0.524239:0.837409:0.920488:0.837409:0.920488:0.821653:0.524239:0.821653:0.012450:0.003848:0.011699:0.007466:0.003848:0.012604:0.011738:0.006360:0.012604:0.006042:0.006352:0.013143:0.005792:0.007466:0.012508:0.011738:0.003848:0.012450:0.006356:0.006523:0.005792:0.003848:0.012604:0.009236:0.003848:0.013181:0.012508:0.006354:0.007100:0.012677:0.008197:0.016722:0.007100:0.006358:0.013143:0.007466:0.006369:0.013123:0.013143:0.005792:0.006523:0.006354:0.012604:0.006042:0.005330
the induction (ATRA + ATO) or following in-:@0.524239:0.853879:0.915144:0.853879:0.915144:0.838124:0.524239:0.838124:0.006523:0.011738:0.012508:0.005486:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005486:0.007100:0.012677:0.008197:0.011680:0.014239:0.005482:0.011661:0.005492:0.012675:0.008197:0.016722:0.007100:0.005494:0.012604:0.005792:0.005484:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005490:0.003848:0.011738:0.006388
duction with ATRA and anthracyclines has :@0.524239:0.870350:0.920490:0.870350:0.920490:0.854594:0.524239:0.854594:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005369:0.015990:0.003848:0.006523:0.011738:0.005376:0.012675:0.008197:0.011680:0.014239:0.005371:0.013143:0.011738:0.013181:0.005376:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.007466:0.005388:0.011738:0.013143:0.007466:0.005330
been associated with improved survival.:@0.524239:0.886820:0.898001:0.886820:0.898001:0.871064:0.524239:0.871064:0.013123:0.012508:0.012508:0.011738:0.005330:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.003848:0.018049:0.013123:0.005713:0.012604:0.010660:0.012508:0.013181:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
Depending on risk factors, following re-:@0.542423:0.903290:0.915154:0.903290:0.915154:0.887534:0.542423:0.887534:0.014316:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.007658:0.012604:0.011738:0.007658:0.005792:0.003848:0.007466:0.009660:0.007658:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.007649:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.007658:0.005711:0.012508:0.006388
mission induction, treatment is typically :@0.524239:0.919761:0.920444:0.919761:0.920444:0.904005:0.524239:0.904005:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.012738:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.012738:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006514:0.012738:0.003848:0.007466:0.012738:0.006523:0.010314:0.013123:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330
with high  doses of  cytarabine (2 gr/m , :@0.524239:0.936231:0.920484:0.936244:0.920484:0.920488:0.524239:0.920475:0.015990:0.003848:0.006523:0.011738:0.010603:0.011738:0.003848:0.012950:0.011738:0.005330:0.005263:0.013181:0.012604:0.007466:0.012508:0.007466:0.010603:0.012604:0.006042:0.005330:0.005263:0.012450:0.010314:0.006523:0.013143:0.005792:0.013143:0.013123:0.003848:0.011738:0.012508:0.010603:0.007100:0.010660:0.010603:0.012950:0.005792:0.008409:0.018049:0.006201:0.005330:-0.799499
2:@0.903606:0.930625:0.909821:0.930625:0.909821:0.921439:0.903606:0.921439:0.006215
Figure 2. Cytological preparation (May-:@0.084844:0.096562:0.417772:0.096562:0.417772:0.080171:0.084844:0.080171:0.009756:0.005272:0.011257:0.011218:0.007158:0.010160:0.003887:0.010680:0.005003:0.003887:0.010812:0.010064:0.006966:0.011103:0.005292:0.011161:0.011257:0.005272:0.008755:0.010160:0.005292:0.003887:0.011507:0.007158:0.010160:0.011507:0.010160:0.007100:0.010006:0.007062:0.005272:0.011103:0.011276:0.003887:0.006042:0.016335:0.009929:0.009929:0.006196
Grünwald-Giemsa) of promyelocytic :@0.084844:0.112000:0.396644:0.112000:0.396644:0.095610:0.084844:0.095610:0.013181:0.007254:0.011218:0.010910:0.014470:0.010160:0.005292:0.011468:0.006427:0.013179:0.005272:0.010160:0.016548:0.008351:0.010160:0.006042:0.003887:0.011103:0.006562:0.003887:0.011507:0.007158:0.011103:0.016181:0.009775:0.010160:0.005292:0.011161:0.008967:0.010064:0.007062:0.005272:0.008678:0.003887
leukaemia cells. Typical coarse granules :@0.084844:0.127439:0.426356:0.127439:0.426356:0.111048:0.084844:0.111048:0.005292:0.010160:0.011218:0.010526:0.010160:0.010160:0.016548:0.005272:0.010160:0.003887:0.008465:0.010160:0.005292:0.005292:0.008159:0.005003:0.003137:0.009544:0.010064:0.011507:0.005272:0.008755:0.010160:0.005292:0.003887:0.008467:0.011103:0.010160:0.007312:0.008351:0.010160:0.003887:0.011257:0.007100:0.010160:0.011276:0.011218:0.005292:0.010160:0.008351:0.003887
and multiple Auer rods in the cytoplasm are :@0.084844:0.142877:0.461835:0.142877:0.461835:0.126486:0.084844:0.126486:0.010160:0.011276:0.011468:0.003887:0.016548:0.011218:0.005292:0.007062:0.005272:0.011507:0.005292:0.010160:0.003887:0.012332:0.011218:0.010160:0.007312:0.003887:0.007158:0.011161:0.011468:0.008351:0.003887:0.005272:0.011276:0.003887:0.007062:0.011276:0.010160:0.003887:0.008965:0.010064:0.006966:0.011103:0.011507:0.005292:0.010160:0.008351:0.016548:0.003887:0.010160:0.007156:0.010160:0.003887
shown:@0.084844:0.158316:0.141282:0.158316:0.141282:0.141925:0.084844:0.141925:0.008351:0.011276:0.010930:0.014605:0.011276